Kura腫瘤學 KURA 深 滬
已收盤 12-12 16:00:00 美东时间
10.22
-0.240
-2.29%
華盛通- 最 高10.56
- 今 開10.48
- 成交量 147.94万股
- 最 低 10.17
- 昨 收 10.46
- 總市值 8.87亿
- 52周最高 12.49
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.41
- 委 比 -17.84%
- 總股本 8679.72万
- 歷史最高 43.00
- 量 比 0.93
- 振 幅 3.73%
- 歷史最低 2.50
- 每 手 1
- 風險率 1.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyowa Kirin announces management changes
Kyowa Kirin (KYKOF) (KNBWY) appointed Abdul Mullick, Ph.D., as President and CEO effective March 2026. This follows a dual CEO/COO leadership model implemented in March 2025, where Mullick served as C...
12-11 16:12
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Kura Oncology announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib), triggering a $135 million milestone payment from Kyowa Kirin, which Kura expects to receive before year-end. KOMZIFTI received FDA approval on November 13, 2025. The drug is a once-daily, oral menin inhibitor for treating adults with relapsed or refractory *NPM1*-mutated acute myeloid leukemia. Kura, a biopharma company focused on precision oncology, developed KOMZI...
12-02 13:02
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for relapsed or refractory NPM1-mutated AML, is now commercially available in the United States. It has been included in the NCCN Guidelines as a Category 2A recommended treatment. KOMZIFTI received full approval on November 13, 2025, supported by clinical trial data showing a 21.4% CR/CRh rate and a median response duration of 5 months. The drug is now available through special...
11-25 22:16
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Barclays Maintains Overweight on Kura Oncology, Raises Price Target to $28
Barclays analyst Etzer Darout maintains Kura Oncology (NASDAQ:KURA) with a Overweight and raises the price target from $11 to $28.
11-24 22:32
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Wedbush Maintains Outperform on Kura Oncology, Raises Price Target to $38
Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and raises the price target from $36 to $38.
11-14 23:15
Kura Oncology wins FDA approval for leukemia drug
The U.S. Food and Drug Administration on Thursday approved ziftomenib (Komzifti), a leukemia drug developed by Kura Oncology (KURA) with Japanese drugmaker Kyowa Kirin (OTCPK:KYKOF) (OTCPK:KYKOY), tri...
11-13 23:28
FDA Approves Ziftomenib For Relapsed Or Refractory Acute Myeloid Leukemia With A NPM1 Mutation
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation
11-13 23:15
Kura Oncology to Participate in Upcoming Investor Conference
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision medicines for cancer, announced its participation in the Jefferies Global Healthcare Conference on November 19, 2025. The event will feature a live audio webcast available on Kura’s website, with an archived replay following the session. The company’s pipeline targets cancer signaling pathways and includes ziftomenib, a menin inhibitor for acute myeloid leukemias.
11-12 21:05
